Charlotte Allerton

Meet Charlotte Allerton

In nearly 30 years at Pfizer, Charlotte and her team have been instrumental in discovering and developing breakthrough treatments. She currently leads an R&D organization of 3,000+ members, focused on advancing research and development in areas of critical unmet need. Charlotte has contributed to the approval of several key medicines, including Paxlovid to combat COVID-19; Litfulo for alopecia; and Lorbrena for non-small cell lung cancer. She and her team have also significantly improved phase II success rates in drug development by leveraging molecular design and innovative clinical development paradigms. 

“We need to paint a compelling picture of the transformational impact that talented scientists can have on addressing the world's greatest healthcare challenges. This will inspire people to join and make a real difference. There is also tremendous opportunity in drug discovery to continue to advance specific scientific disciplines, and to publish, teach, and push the boundaries of the field.”

^{Image credit: EPNAC.com}